What people are saying.
Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering
Allogene Therapeutics Announces Scientific Advisory Board
Allogene Therapeutics Announces Board of Directors
Kronos Bio Appoints Dr. Norbert Bischofberger, Former Head of R&D for Gilead Sciences, as President and Chief Executive Officer and Completes $18 Million Seed Financing
Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline
Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies